Durvalumab: tested on its own

110 studies: no other medicine in its arm. Page 1 of 2. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic CholangiocarcinomaRecruitingNCT07766187Phase 2Report a problem
• Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung CancerNot yet recruitingNCT07759492Phase 2Report a problem
• Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal CancerNot yet recruitingNCT07565857Not applicableReport a problem
• TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal AdenocarcinomaNot yet recruitingNCT07507968Phase 2Report a problem
• Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLCNot yet recruitingNCT06998719Phase 2Report a problem
• Chemoradiotherapy With Surgery Followed by Consolidation DurvalumabRecruitingNCT06908070Phase 4Report a problem
• Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialRecruitingNCT06498635Phase 3Report a problem
• AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMARecruitingNCT06464068Phase 2Report a problem
• Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and ResectionRecruitingNCT06331455Phase 2Report a problem
• A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO StudyRecruitingNCT06290505Phase 2Report a problem
• A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.RecruitingNCT06284317Phase 3Report a problem
• Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung CancerRecruitingNCT05696782Phase 2Report a problem
• Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular FeaturesRecruitingNCT05255653Phase 3Report a problem
• Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.RecruitingNCT05128630Phase 2Report a problem
• Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)RecruitingNCT04585477Phase 2Report a problem
• The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)Not yet recruitingNCT04517227Not applicableReport a problem
• Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.RecruitingNCT04202809Phase 2Report a problem
• Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLCRecruitingNCT03694236Phase 1/2Report a problem
• Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular CarcinomaCompletedNCT04945720Phase 2Results postedReport a problem
• Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.CompletedNCT04642469Phase 3Results postedReport a problem
• Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLCTerminatedNCT04441138Phase 2Results postedReport a problem
• Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLCCompletedNCT04416633Phase 4Results postedReport a problem
• DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaCompletedNCT04334759Phase 3Results postedReport a problem
• Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for ChemotherapyCompletedNCT04249362Phase 2Results postedReport a problem
• CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung CancerActive, not recruitingNCT04062708Phase 2Results postedReport a problem
• Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung CancerCompletedNCT04003246Phase 2Results postedReport a problem
• Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)Active, not recruitingNCT03875235Phase 3Results postedReport a problem
• A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsActive, not recruitingNCT03706690Phase 3Results postedReport a problem
• A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung CancerCompletedNCT03693300Phase 2Results postedReport a problem
• Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHNCompletedNCT03529422Phase 2Results postedReport a problem
• Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the PancreasTerminatedNCT03490760Phase 2Results postedReport a problem
• Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal CancerCompletedNCT03435107Phase 2Results postedReport a problem
• Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take CisplatinCompletedNCT03258554Phase 2/3Results postedReport a problem
• RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid CancersActive, not recruitingNCT03215095Early Phase 1Results postedReport a problem
• Durvalumab in HIV-1 Patients With Solid TumorsCompletedNCT03094286Phase 2Results postedReport a problem
• Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)Active, not recruitingNCT03003962Phase 3Results postedReport a problem
• Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung CancerCompletedNCT02904954Phase 2Results postedReport a problem
• Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the BladderTerminatedNCT02901548Phase 2Results postedReport a problem
• Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable MesotheliomaCompletedNCT02899195Phase 2Results postedReport a problem
• Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the BladderTerminatedNCT02891161Phase 1/2Results postedReport a problem
• A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer PatientsCompletedNCT02879617Phase 2Results postedReport a problem
• Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx CancerTerminatedNCT02827838Early Phase 1Results postedReport a problem
• Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersCompletedNCT02766335Phase 2/3Results postedReport a problem
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsTerminatedNCT02669914Phase 2Results postedReport a problem
• A Study of Durvalumab (MEDI4736) in Esophageal CancerCompletedNCT02639065Phase 2Results postedReport a problem
• Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)CompletedNCT02572843Phase 2Results postedReport a problem
• Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast CancerCompletedNCT02489448Phase 1/2Results postedReport a problem
• Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCCompletedNCT02273375Phase 3Results postedReport a problem
• Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal CancerCompletedNCT02227667Phase 2Results postedReport a problem
• Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02207530Phase 2Results postedReport a problem
• A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerCompletedNCT02125461Phase 3Results postedReport a problem
• A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02087423Phase 2Results postedReport a problem
• A Phase 1/2 Study to Evaluate MEDI4736CompletedNCT01693562Phase 1/2Results postedReport a problem
• Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.Active, not recruitingNCT06992609Phase 3Report a problem
• --SuPERIOR Trial--TerminatedNCT06191250Phase 2Report a problem
• Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Active, not recruitingNCT05925530Phase 2Report a problem
• A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)CompletedNCT05924880Phase 3Report a problem
• Using Circulating Tumor DNA to Personalize Duration of Consolidation DurvalumabWithdrawnNCT05757843Phase 2Report a problem
• Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the ThoraxActive, not recruitingNCT05617963Phase 2Report a problem
• Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC RegimenTerminatedNCT05443971Phase 1Report a problem
• Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or ChemoradiotherapyStatus unknownNCT05267392Phase 1/2Report a problem
• Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II StudyStatus unknownNCT05262985Phase 2Report a problem
• Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)Active, not recruitingNCT05215106Phase 2Report a problem
• Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)Active, not recruitingNCT05206812Phase 2Report a problem
• Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung CancerStatus unknownNCT05034133Phase 2Report a problem
• SCION: SABR and Checkpoint Inhibition of NSCLCWithdrawnNCT04944173Phase 2Report a problem
• SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular CarcinomaStatus unknownNCT04913480Phase 2Report a problem
• Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell CarcinomaStatus unknownNCT04851132Not applicableReport a problem
• Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation TherapyActive, not recruitingNCT04716946Phase 2Report a problem
• Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)Active, not recruitingNCT04602533Phase 2Report a problem
• Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBCStatus unknownNCT04543110Phase 2Report a problem
• Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker StudyActive, not recruitingNCT04392505Phase 2Report a problem
• Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus InfectionCompletedNCT04294498Phase 2Report a problem
• Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal CancerStatus unknownNCT04293419Phase 2Report a problem
• Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04245514Phase 2Report a problem
• Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung CancersCompletedNCT04230408Phase 2Report a problem
• Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCCCompletedNCT04124991Phase 1/2Report a problem
• Diadem to Investigate the Activity and Safety of DurvalumabCompletedNCT04115111Phase 2Report a problem
• Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal CancerTerminatedNCT04108481Phase 1Report a problem
• Immunotherapy in Patient With Poor General ConditionCompletedNCT04108026Phase 2Report a problem
• Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell CarcinomaStatus unknownNCT04054518Phase 2Report a problem
• Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung CancerCompletedNCT03999710Phase 2Report a problem
• Imaging Tumor-infiltrating T-cells in Non-small Cell Lung CancerCompletedNCT03853187Phase 2Report a problem
• PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCCCompletedNCT03829007Phase 1/2Report a problem
• Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder CancerActive, not recruitingNCT03768570Phase 2Report a problem
• Efficacy of Durvalumab in Non-muscle-invasive Bladder CancerStatus unknownNCT03759496Phase 2Report a problem
• Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHNCompletedNCT03726775Phase 2Report a problem
• Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving DurvalumabActive, not recruitingNCT03653052Phase 2Report a problem
• Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell CarcinomaCompletedNCT03635164Phase 1Report a problem
• 1st Line Durvalumab in PS 2 NSCLC PatientsActive, not recruitingNCT03620669Phase 2Report a problem
• A Trial of Radiotherapy and Durvalumab in DLBCL and FLCompletedNCT03610061Phase 1Report a problem
• Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung CancerStatus unknownNCT03585998Phase 2Report a problem
• Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)CompletedNCT03446547Phase 2Report a problem
• A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell AdenocarcinomasStatus unknownNCT03405454Phase 2Report a problem
• PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.Status unknownNCT03283943Phase 1Report a problem
• Radiation Therapy in Combination With Durvalumab for People With Pancreatic CancerActive, not recruitingNCT03245541Phase 1/2Report a problem
• Durvalumab in DLBCL After Autologous TransplantWithdrawnNCT03241017Phase 2Report a problem
• Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaWithdrawnNCT03235869Early Phase 1Report a problem
• A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone PlasmacytomaWithdrawnNCT03196401Phase 1Report a problem
• Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body RadiotherapyTerminatedNCT03148327Phase 1/2Report a problem

← Durvalumab